Showing: 1 - 10 of 21 RESULTS

Envisioning a Better World by Transforming the Future of Healthcare

New Book Presents Non-Partisan, Solutions-Based Approach to Healthcare For All

Washington, D.C., Oct. 13, 2020 (GLOBE NEWSWIRE) — The global COVID-19 pandemic made apparent that the existing public policy and current healthcare systems are ill-prepared to deal with the global challenges of providing quality and affordable healthcare; still, a non-partisan solution to healthcare reform has yet to land on the table.

Until now.

In their book, Beyond the COVID-19 Pandemic: Envisioning a Better World by Transforming the Future of Healthcare, authors Ambassador Pradeep K. Kapur and Dr. Joseph M. Chalil present SafetyNet, a healthcare-for-all policy, based on decades of experience in public policy and healthcare management, that challenges the world to have the political consensus to create meaningful change for all—both in the United States and worldwide.

Endorsed by policymakers, thought leaders, Ambassadors worldwide, leading healthcare professionals, and best-selling authors, Beyond the COVID-19 Pandemic asks the questions: what if it’s not reform we need, but instead a revolution? What if we reimagined a healthcare system with patients, not big pharma and insurance companies, in the driver’s seat?

For a solutions-based, scientifically, and data-driven approach to Healthcare For All, explore Ambassador Kapur and Dr. Chalil’s Beyond the COVID-19 Pandemic—available today.

 

About the Authors:

Ambassador Pradeep K. Kapur is an acknowledged “luminary diplomat,” with a distinguished career working with leaders and policymakers around the world. Author and editor of many books, he was Ambassador of India to Chile and to Cambodia, as well as Secretary at the Indian Ministry of External Affairs. 

His healthcare contributions include setting up the acclaimed bilateral India Nepal initiative, the BP Koirala Institute of Health Sciences. Additionally, he brings decades of global public policy experience and historical perspectives to the solutions that make Beyond the COVID-19 Pandemic: Envisioning a Better World by Transforming the Future of Healthcare unique.

A graduate of the globally acclaimed Indian Institute of Technology, Delhi (IIT-D), he is Executive Director of Smart Village Development Fund (SVDF) of the WHEELS Global Foundation. 

Dr. Joseph M. Chalil, an author of several scientific and research papers in international publications, is the Chairman of the Complex Health Systems Advisory Board, H. Wayne Huizenga College of Business and Entrepreneurship at Nova Southeastern University in Florida and a member of Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD) Executive Leadership Council. 

A veteran of the U.S. Navy Medical Corps, he is board certified in healthcare management. He has been awarded a Fellowship by the American College of Healthcare Executives, an international professional society of more than 40,000 healthcare executives who lead hospitals, healthcare systems, and other healthcare organizations. 

He is an expert in U.S. healthcare policy and a strong advocate for patient-centered care. With over two decades of experience working in the U.S. healthcare system, he discusses healthcare delivery challenges, including providing quality, affordable patient care to all, and alternate templates for health insurance.

 

More Information:

Paperback: 276 pages

Publisher: TheUNN Corporation, October 5, 2020

Language: English

ISBN-10: 1735904813

ISBN-13: 978-1735904818

Product

Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Jefferies Virtual Global Healthcare Conference on November 17-19. In one-on-one sessions, the Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cancer cell metabolism, SM-88 (racemetyrosine) late-stage trials in pancreatic cancer, SM-88 HopES trial in ultra-rare metastatic sarcoma, proof-of-concept RESPOnD™ trial evaluating TYME-19 in COVID-19, and expanding clinical plans for its cancer-metabolism pipeline candidate SM-88 in prostate, breast and hematological cancers.

Event: Jefferies Virtual Global Healthcare Conference
Place: Waldorf Hilton, London
Presentation Date: November 17-19, 2020
Format: One-on-one sessions

The presentation will be accessible on the events page under the investor relations section of Tyme Technologies’ website at www.tymeinc.com.

About SM-88

SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events. Learn more.

About TYME-18

TYME-18 is composed of a proprietary surfactant delivery agent with a specific sulfonic acid component. It is designed for intra-tumoral administration of difficult to treat tumors and leverages the acidic tumor microenvironment and signaling pathways to kill cancer cells. TYME-18 is distinct in composition, but like SM-88, aims to leverage susceptibilities of a cancer that are related to its altered metabolism. Initial preclinical data for TYME-18 in animal tumor models demonstrate rapid and complete tumor regression, with no reported local or systemic toxicities. TYME-18 continues to be studied as a potential therapy for difficult to treat tumors that may not be eligible for surgical or other interventions. Learn more.

About TYME-19

TYME-19 is a potent, well characterized synthetic antiviral bile acid that is being evaluated as a potential oral therapy for COVID-19. In preclinical testing, TYME-19 repeatedly prevented COVID-19 viral replication without attributable cytotoxicity in treated cells. COVID-19 hijacks a cell’s ability to make proteins and lipids and divert these processes to make viral proteins and lipids in order to reproduce. COVID-19 accomplishes this by inducing stress in the endoplasmic reticulum (ER), where cells process proteins, which enables the virus to remodel protein and lipid synthesis. In preclinical testing, TYME-19 has been shown to counteract these effects, preventing viral replication, by reducing ER stress. TYME-19 is believed to physically degrade viruses by solubilizing the protective lipid layer and other structural components, which prevent a virus from binding to and infecting a cell.

About TYME-88-Panc Pivotal Trial

The TYME-88-Panc pivotal trial applies the latest advances in the field of cancer metabolism by evaluating the efficacy and safety of an oral investigational compound that targets the metabolic mechanisms of the

Hartford HealthCare and Connecticut Children’s broaden partnership extending pediatric care

The top executives of Hartford HealthCare and Connecticut Children’s on Monday signed an agreement broadening a 25-year partnership to combine pediatric services with the hospital system’s extensive network across Connecticut.

“This is a continuation and expansion and formalization of an existing relationship,” James Shmerling, president of Connecticut Children’s, said at an announcement outside Hartford Hospital.

Jeffrey Flaks, president of Hartford HealthCare, promised investments and modernization of services at neonatal intensive care units as Connecticut Children’s services are moved into Hartford HealthCare facilities.

“We’re going to work perfect the hand-off when children become adolescents and adolescents become adults for their health care,” he said.

Hartford HealthCare includes two tertiary-level teaching hospitals, an acute-care community teaching hospital, an acute-care hospital and trauma center, three community hospitals, a behavioral health network and a multispecialty physician group.

Stephen Singer can be reached at [email protected]

———

©2020 The Hartford Courant (Hartford, Conn.)

Visit The Hartford Courant (Hartford, Conn.) at www.courant.com

Distributed by Tribune Content Agency, LLC.

Source Article

Alignment Healthcare Adds MemorialCare Hospitals and Doctors to 2021 Medicare Advantage Provider Network

Nationally ranked nonprofit health system and Medicare Advantage insurance provider sign agreement to expand access to care for Medicare-eligible beneficiaries in Southern California

MemorialCare, a leading nonprofit health system in Southern California with hundreds of primary care and specialty providers, four top hospitals and 200 locations, is joining Alignment Healthcare’s Medicare Advantage provider network starting Jan. 1, 2021, expanding its scope of coverage to 2 million Medicare-eligible residents in Los Angeles and Orange counties.1

This means that Medicare beneficiaries who enroll in select plans from Alignment – named one of four 2020 Best Insurance Companies for Medicare Advantage in California by U.S. News & World Report – will have access to MemorialCare’s hospitals, health centers and urgent care locations and may seek “in-network” care from physicians associated with MemorialCare Medical Foundation. Medicare’s annual enrollment period for the 2021 plan year begins Oct. 15.

“As part of Alignment’s network, we will ensure that more people will have increased access to MemorialCare’s renowned services,” said Mark Schafer, M.D., CEO, MemorialCare Medical Foundation, which includes MemorialCare Medical Group, Greater Newport Physicians, and Edinger Medical Group. “MemorialCare has a long, 113-year history of providing quality care to Southern California communities, and joining Alignment’s network allows us to continue delivering on that commitment.”

Alignment Healthcare continues to grow and recently announced in August that it plans to expand its Medicare Advantage plans into several new markets across California, Nevada, and North Carolina starting in 2021. Alignment’s health care delivery model – powered by its proprietary command center technology AVA™ – and ACCESS On-Demand Concierge program, launched in 2019, offers its Medicare Advantage members white-glove service such as round-the-clock access to a doctor by phone or video, a dedicated concierge team, and a black benefits card that can be used like a debit card – all at no additional cost. Depending on their plan, members receive a monthly allowance automatically loaded onto their black card to purchase eligible over-the-counter and grocery benefit items at more than 50,000 retailers nationwide.

“At Alignment Healthcare, we are always looking for ways to make our members happy, and we hope they will be pleased with having access to MemorialCare’s top-rated doctors, hospitals and services,” said Dawn Maroney, president of consumer and markets, Alignment Healthcare. “This announcement is also an important consideration for Southern Californians who are making a decision about their 2021 Medicare coverage during this year’s Medicare Annual Election Period – to know what health care providers will be available to them in their health plan’s network when they need it in 2021.”

MemorialCare’s Long Beach Medical Center, Orange Coast Medical Center, Saddleback Medical Center and Miller Children’s & Women’s Hospital Long Beach have been recognized by U.S. News & World Report as one of America’s Best Hospitals and “high performing” in numerous clinical categories since the rankings began. In addition, MemorialCare Medical Foundation comprises more than 350 primary care physicians and 2,250 specialists in the areas of internal medicine, family medicine, pediatrics, geriatric medicine, pulmonology,

Diamond Dental Associates LLC, Has The Best Flemington Dentist For Oral Healthcare And Treatment Needs

Diamond Dental Associates LLC, Has The Best Flemington Dentist For Oral Healthcare And Treatment Needs

Flemington, NJ – Members of the Flemington, NJ community who wish to sport the best smiles and enjoy the advantages of top oral health can rest assured that Diamond Dental Associates LLC has the best dentists in the area to deliver these premium services at the most affordable prices. At Diamond Dental Associates LLC, the dental team focuses on providing premium quality dental care and treatment solutions to patients while delivering the best dental experience in the process.

As the leading dental clinic in the area, Diamond Dental Associates LLC has a team of dentists with over three decades of experience who are on the ground to listen to oral health complaints from patients and address the problem. At Diamond Dental Associates LLC, the team employs the use of the latest dental technologies to establish diagnosis and craft treatment plans that are most suitable for the needs of each patient.

Promising the very best dental experience, the top Flemington Dentist at the clinic said: “Here at Diamond Dental Associates LLC, we pledge to provide the finest personal service using state of the art technology for our patients, who will always be welcomed to a warm and caring environment. At Diamond Dental Associates we change lives one smile at a time. We are committed to making every interaction with our patients a positive one. We respect and acknowledge your concerns about the dental treatment you will receive. We recognize that it is difficult for highly fearful people to visit a dental office for needed treatment and we offer services that help you to feel confident that the treatment we provide is in your best interests and fits in with your preferences, lifestyle, and monetary investment.”

As a dental clinic that is constantly working on new ways to address the dental care and treatment needs of patients, Diamond Dental Associates LLC – Flemington Dentist has expanded the services offered to include general dentistry practice which focuses on improving oral health and protecting the mouth from common debilitating conditions. As part of the general dentistry services offered, patients will get to enjoy routine dental examinations, oral cancer screening, teeth cleaning, dental sealants, and more.

Added to this, the dental team at Diamond Dental Associates LLC also offers a wide range of cosmetic dental solutions aimed at improving the appearance and appeal of the teeth. As part of the cosmetic dental solutions offered, patients are welcomed into the clinic to enjoy teeth whitening services aimed at brightening the teeth and smile; cosmetic bonding used to restore decayed teeth, strengthen a weak tooth, close spaces between the teeth, and alter the shape and/or size of the tooth.

The dentists also offer dental veneers that are used to cover up blemishes, chips, cracks, and tooth discoloration; dental implants for restoration of missing or lost teeth; as well as sports mouthguards and sleep apnea treatment.

Visit Diamond Dental Associates LLC at North, 334 NJ-31 #1, Flemington, NJ 08822, or call 908-838-0004. For more information, send an email

Investors eye discounted U.S. healthcare sector as Biden’s lead in polls grows

By Lewis Krauskopf



FILE PHOTO: Pharmaceutical tablets and capsules are arranged on a table in this picture illustration taken in Ljubljana


© Reuters/Srdjan Zivulovic
FILE PHOTO: Pharmaceutical tablets and capsules are arranged on a table in this picture illustration taken in Ljubljana

NEW YORK (Reuters) – Investors are looking for bargains among healthcare stocks, even as prospect of a Democratic “Blue Sweep” in next month’s elections threatens more volatility for a sector already trading near a historical discount to the broader market.

Loading...

Load Error

A victory by former Vice President Joe Biden over President Donald Trump on Nov. 3 and a potential Democratic takeover of the Senate could clear the way for prescription drug price and healthcare coverage reforms, generally seen as potential negatives for companies in the sector.

Some investors are betting these factors have already been priced into healthcare shares or may not be as detrimental as feared, while the companies stand to benefit from relatively stable earnings prospects and their medical innovations.

“For high-quality companies that are trading at reasonable valuations … there is a strong argument to be made for adding some healthcare exposure to portfolios,” said James Ragan, director of wealth management research at D.A. Davidson.

Biden’s improving election prospects have weighed on healthcare stocks for much of 2020, according to investors, with the S&P 500 healthcare sector <.spxhc> climbing just 7% since the end of April, against a 17% gain for the overall S&P 500 <.spx>.

A Reuters/Ipsos poll on Sunday showed Biden opened his widest lead in a month after Trump contracted COVID-19.

The healthcare sector now trades at a 26% discount to the S&P 500 on a price-to-earnings basis, according to Refinitiv Datastream. The sector’s 15.8 P/E ratio is well below the S&P 500’s 21.3 ratio, which last month rose to its highest valuation since 2000.

The gap between the sector’s P/E ratio and that of the S&P stood at its widest in at least 25 years last month, though it has narrowed in recent weeks.

“As Biden started to do better in the polls, you saw healthcare start to underperform a bit as the rest of the market recovered,” said Ashtyn Evans, a healthcare analyst with Edward Jones.

While Biden may shake up insurance coverage by offering a “public option” government plan, he is also expected to seek to strengthen the Affordable Care Act – the signature healthcare law enacted when he was vice president – under which companies are used to operating.

Any significant drug pricing legislation may need to wait until the pandemic is more contained, as the government relies on the pharmaceutical industry to develop COVID-19 therapies and vaccines. Trump has also vowed to lower drug prices, making the issue arguably less partisan.

“We think there remains a reasonably good probability that the next Congress will institute moderate health policy changes that will create long-term clarity for the sector and investors,” Eric Potoker, an analyst at UBS Global Wealth Management, said in a note last month.

Healthcare stocks have been prone to volatility around elections.

Ahead of the 2016 vote, which pitted Trump against former Secretary of

HCA Houston Healthcare North Cypress offers preventative gene testing for breast cancer

When Dalyss Tomayer found out three of her relatives had had breast cancer, it was enough to qualify her for the genetic testing which showed she had a high risk of breast cancer herself.

Tomayer was able to discover the gene early due to getting tested at HCA Houston Healthcare North Cypress’ High Risk Breast Clinic, where they offer genetic testing for those who qualify to see if they may have the BRCA1 or BRCA2 gene which puts people at higher risk for breast cancer.

“I had known for years that two of my dad’s sisters had breast cancer, and it was in speaking with one of my aunts that I then found out also one of my cousins had breast cancer,” Tomayer said. “So, it was at that time that I realize that I did qualified for the genetic testing and I decided to go ahead and do it.”

Janet Pollard, the coordinator for the High Risk Breast Clinic, said the breast center began as a full program under HCA Houston North Cypress’ CEO Jim Brown, who she said was passionate about having this resource.


“Most of the time people think about genetic testing after you get cancer,” Pollard said. “It can drive the type of surgeries, it can change treatment regime, but basically it’s getting it done prior. It’s screening people when they come in for their annual mammograms, talking with primary care doctors, educating them on what makes patients meet criteria.”

Criteria established by the American Cancer Society for genetic testing includes people who were diagnosed with breast cancer at a younger age, those diagnosed with breast cancer a second time, people of Ashkenazi Jewish descent, people with a family history of breast cancer, ovarian cancer, pancreatic cancer or prostate cancer, and people with a known family history of BRCA mutation.

Before the pandemic, Pollard said the center was testing around 30 people a month, men and women, with about 10 percent of people testing coming back positive.

“BRCA1 and 2 genes are huge red flags,” Pollard said. “They’re the original genes and they’ve been testing those genes for two decades.”

The process Tomayer chose to go through after being tested was to have a double mastectomy to virtually remove all chance of breast cancer, as well as a hysterectomy to eliminate her chances of ovarian cancer.

“Even though you do a double mastectomy, there’s no way to get 100 percent of every breast cell in my body, so there is still a slight chance, but it is incredibly slight,” she said.

Tomayer said she would continue to have ultrasounds for what remaining breast tissue she has left.

“I’m so very thankful they have the test,” Tomayer said. “It saved my life.”

[email protected]

Source Article

Laurie Delgado Named Vice President of Appeals and Grievances for Beacon Healthcare Systems

Delgado Brings Two Decades of Leadership Experience in Medicare A&G to Oversee Beacon’s Industry-Leading Virtual Appeals Manager Tool

Laurie Delgado, who over the past two decades has overseen Medicare appeals and grievances for two of the nation’s largest and most highly respected health plans, has been named vice president of appeals and grievances for Beacon Healthcare Systems, effective immediately. Beacon is home to the health care industry’s leading compliance and risk management technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006005960/en/

Laurie Delgado, Vice President of Appeals and Grievances, Beacon Healthcare Systems (Photo: Business Wire)

For the past five years, Delgado has served as director of Medicare grievances and appeals for Anthem where she led and developed a team of over 120 staff, including clinicians, auditors, analysts and support personnel to achieve a level of excellence in handling customer appeals with strict compliance of regulatory processes and timeframes. Immediately prior she served in a similar role for UnitedHealth Group where over an 18-year career she was responsible for various aspects of appeals and grievances operations, project management and process improvement.

At Beacon, Delgado will oversee the company’s highly acclaimed Virtual Appeals Manager (VAM), the industry’s most intuitive and easy-to-use appeals and grievances tool. Designed by health plan compliance and operational experts, VAM is a highly configurable and automated solution that can be implemented in record time and provides unparalleled control and transparency of cases from intake to review, thus ensuring complete compliance with the Centers for Medicare & Medicaid Services. VAM also helps reduce a massive amount of health plan letters into a manageable and efficient core of templates. As a result of its reliability, transparency and ease of use, VAM has been shown to improve star ratings, translating into additional dollars from CMS to the health plan that can be investing into better serving members.

“We are thrilled to have someone with Laurie’s leadership experience join our team and oversee the products and capabilities we offer our health plan clients in the area of appeals and grievances,” said Beacon CEO Ken Stockman. “Her deep experience with government regulations, compliance standards and process improvement will help us achieve an even greater footprint in the Medicare Advantage space as we continue to develop innovative solutions that our customers and their members find of enormous value.”

Beacon Healthcare Systems is home to the health care industry’s leading compliance and risk management technologies, providing health plans of all sizes and sponsorships with customizable and scalable SaaS (Service as a Software) solutions that ensure accountability, accuracy and operational efficiency. With a focus on appeals, grievances, compliance and analytics, Beacon HCS is the first place health plans turn to when they are looking for a trusted, experienced partner who can help them reduce costs, grow revenue and achieve their strategic goals. Founded in 2011, Beacon HCS is a privately held California-based company with a technology center located in Austin, Texas. beaconhcs.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005960/en/

Contacts

Pamela Raley

Europe Animal Healthcare Market to Surpass US$ 17,837.8 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the Europe animal healthcare market is estimated to be valued at US$ 13,119.7 million in 2020 and is expected to exhibit a CAGR of 4.5% over the forecast period (2020-2027).

Key Trends and Analysis of the Europe Animal Healthcare Market:

Key trends in the market are rising incidence of zoonotic viral pathogens, increasing demand for protein from animal sources, and government initiatives to provide improved animal healthcare.

Market players are focused on launches and approvals of products for better offerings in the market. For instance, in August 2017, Boehringer Ingelheim launched Centragard, a transdermal solution for the treatment and control of three most common intestinal parasites in cats such as hookworms, roundworms, and tapeworms.

Increasing adoption of various growth strategies by market players such as investments in order to maintain a competitive edge in the market is expected to drive the market growth. For instance, in July 2018, Boehringer Ingelheim announced investment of around US$ 221 million for establishing a production center to cater to the increasing demand for drugs of foot-and-mouth disease and Bluetongue virus.

The most common zoonotic viral diseases diagnosed in Europe over the past few years include rabies, influenza virus, Rift Valley fever, dengue fever, West Nile fever, crimean-congo hemorrhagic fever, and others. According to the HealthforAnimals Association, around 60% of diseases in the world are zoonotic, which are responsible for 2.4 billion cases of human illnesses and 2.2 million deaths, annually.

Furthermore, companies and the subsidiaries operating in the Europe intend to leverage their proprietary technologies for the development of novel therapeutics to treat serious medical conditions in pets. For instance, in 2017, OPKO Health Spain evaluated Enko 1 for use in companion animals. Enko 1 is a patented intra-articular injectable hyaluronic acid and chondroitin sulfate complex to relieve pain.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/550

However, stringent regulations on sales and usage of antibiotics, and high cost of animal healthcare services are major factors hindering the market growth. Antimicrobial resistance (AMR) is a major concern limiting the usage of antibiotics, which has resulted in lesser use of antibiotics. In 2015, the Europe government published guidelines regarding the proper use of antimicrobial agents in veterinary medicine to control AMR in animals, which has led to various restrictions.

Key Market Takeaways:

The Europe animal healthcare market is expected to exhibit a CAGR of 4.5% over the forecast period, owing to rising incidence of zoonotic viral pathogens, increasing demand for protein from animal sources, increasing government initiatives to provide improved animal healthcare, and adoption of inorganic growth strategies such as acquisitions and collaborations by market players. For instance, in February 2019, UNION Therapeutics A/S and Ceva Santé Animale S.A. partnered for the development of UNI836 for treating canine pyoderma in companion animals.

Key players in the market are focused on product approvals and launches to enhance their product portfolio, which in turn is expected to propel the market growth over the forecast period. For instance, in September 2015,

Medicine’s Changing View Of Racism Towards Healthcare Professionals

Almost a decade ago, I was subject to a racist tirade by a patient.

The patient told me, “Why don’t you go back to India?”  

I responded angrily to the patient: “Why don’t you leave this [expletive] hospital?” 

I sought guidance on how to cope with and respond to the patient’s racism and found little.  The institution at which I worked had no policies in place that guided my response.

I had the patient’s care reassigned to other physicians and subsequently wrote about my experience and reflections in an essay called, “The Racist Patient,” that was published in the Annals of Internal Medicine and featured in the New York Times.

My conclusion: there were limits to service and the abuse to which we might accept as healthcare professionals.

The essay generated controversy and drew two different kinds of responses.

The first set of responses was from sympathetic physicians with like experiences who felt unprotected by the institutional cultures in which they worked.  

I heard from an African American physician whose hospital routinely reassigned patients from his care so as to not compromise their patient satisfaction results.

I heard also from a pharmacist whose management accommodated a patient request to not have “that Paki touching [their] meds or speaking to [her] about them so make sure the other pharmacist is available.”  

One Vietnamese-American academic physician wrote:

“I am of Vietnamese-descent and your article had a resounding impact on me.  I have experienced such overt racist and sexist comments in my career made so much more difficult when it is directed at me as an attending physician and in front of my residents.”

The second, more dominant set of responses was from physicians who held the view that healthcare professionals are somehow held to a higher ethical standard, that the unwritten code of professionalism requires us to ignore our own feelings and continue to care for patients regardless of their views.

One physician wrote an extensive letter to me in response:

“The tone and words in your article demonstrate to me that you have a long way to travel, not to India or anywhere else, but to a place in your heart that tells you that being a good doctor means that patients, even difficult patients, deserve better treatment than that which you gave to [the patient]….But upon further reflection you arrogantly felt justified in not apologizing to him because ‘there are clear limits’ to your service. Yes, doctors are not slaves, submitting to any kind of abuse but your….response was not professional.”

Another physician wrote a published letter to the Annals of Internal:

“His complaint was legitimate…You missed an opportunity to heal and win over a fellow man.”

I certainly regretted my angry instinctual initial response—but also felt that the traditional institutional perspective on abusive, racist patients is medicine’s own version of “the customer is always right.” Being a medical